Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation

Radiation Oncology

Jinming Yu³  Li Kong³  Fang Shi³  Minghuan Li³  Jingyu Luo¹  Anqin Han³  Yongmin Bi²  Hui Zhu³ 

[1] Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China;Department of Radiology, the Airforce General Hospital of Chinese People’s Liberation Army, Beijing, China;Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jiyan Rd. 440, Jinan 250117, Shandong Province, China

关键词: Pathologic stage;    Lymphovascular invasion;    Risk factors;    Prophylactic cranial irradiation;    Brain metastases;    Small cell lung cancer;   

Others  :  1151276
DOI  :  10.1186/1748-717X-9-216

 received in 2014-06-10, accepted in 2014-09-16,  发布年份 2014

【 摘 要 】

Background

The role of prophylactic cranial irradiation (PCI) on small cell lung cancer (SCLC) has been established based on the two-stage system of limited versus extensive disease and the treatment modality of chemoradiotherapy. However, the use of PCI after combined-modality treatment with surgery for resectable limited-stage SCLC has not been investigated sufficiently. We conducted a retrospective study to evaluate risk factors for brain metastasis (BM) in patients with surgically resected SCLC to identify those most likely to benefit from PCI.

Patients and methods

The records of 126 patients with completely resected SCLC and definitive TNM stage based on histological examination between 2003 and 2009 were reviewed. The cumulative incidence of BM was estimated using the Kaplan–Meier method and differences between the groups were analyzed using the log-rank test. Multivariate Cox regression analysis was applied to assess the risk factors of BM.

Results

Twenty-eight patients (22.2%) developed BM at some point during their clinical course. The actuarial risk of developing BM at 3 years was 9.7% in patients with p-stage I disease, 18.5% in patients with p-stage II disease, and 35.4% in patients with p-stage III disease (p = 0.013). The actuarial risk of developing BM at 3 years in patients with LVI was 39.9% compared to 17.5% in patients without LVI (p = 0.003). Multivariate analysis identified pathologic stage (hazard ratio [HR] = 2.013, p = 0.017) and LVI (HR = 1.924, p = 0.039) as independent factors related to increased risk of developing BM.

Conclusion

Patients with completely resected p-stage II-III SCLC and LVI are at the highest risk for BM.

【 授权许可】

   
2014 Zhu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
• [2]Bayman NA, Sheikh H, Kularatne B, Lorigan P, Blackhall F, Thatcher N, Faivre-Finn C: Radiotherapy for small-cell lung cancer—Where are we heading? Lung Cancer 2009, 63:307-314.
• [3]Socha J, Kepka L: Prophylactic cranial irradiation for small-cell lung cancer: how, when and for whom? Expert Rev Anticancer Ther 2012, 12:505-517.
• [4]Seute T, Leffers P, ten Velde GP, Twijnstra A: Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004, 100:801-806.
• [5]Komaki R, Cox JD, Whitson W: Risk of brain metastasis from small carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer 1981, 65:811-814.
• [6]Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: a meta-analysis of individual data from 987 patients. N Engl J Med 1999, 341:476-484.
• [7]Patel S, Macdonald OK, Suntharalingam M: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 2009, 115:842-850.
• [8]Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S, EORTC Radiation Oncology Group and Lung Cancer Group: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664-672.
• [9]Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, Olivier KR, Molina JR, Past LR, Adjei AA, North Central Cancer Treatment Group: Prophylactic cranial irradiation in small-cell lung cancer: Findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol 2012, 23:2919-2924.
• [10]National Comprehensive Cancer Network (NCCN) (2011) NCCN Practice Guidelines in Oncology, Version 1Available at http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf webcite (accessed 14 January 2011)
• [11]Fox W, Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 1973, 2:63-65.
• [12]Lad T, Piantadosi S, Thomas P: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106:320-323.
• [13]Badzio A, Kurowski K, Karnicka-Mlodkowska H, Jassem J: A retrospective comparative study of surgery followed by chemotherapy vs nonsurgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 2004, 26:183-188.
• [14]Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, Brahmer J, Rudin CM, Ettinger DS, Yang SC: Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come. J Thorac Cardiovasc Surg 2005, 129:64-72.
• [15]Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, Kato H: Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIA small-cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005, 129:977-983.
• [16]Yu JB, Decker RH, Detterbeck FC, Wilson LD: Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010, 5:215-219.
• [17]de Antonio DG, Alfageme F, Gamez P, Cordoba M, Varela A: Results of surgery in small cell carcinoma of the lung. Lung Cancer 2006, 52:299-304.
• [18]Zhu H, Zhou ZM, Xue Q, Zhang X, He J, Wang L: Treatment modality selection and prognosis of early stage small cell cancer: retrospective analysis from a single cancer institute. Eur J Cancer Care (Engl) 2013, 22:789-796.
• [19]Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, Han P, Choi K, Rotman M: Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010, 116:1350-1357.
• [20]Gong L, Wang QI, Zhao L, Yuan Z, Li R, Wang P: Factors affecting the risk of brain metastasis in small cell lung cancer with surgery: is prophylactic cranial irradiation necessary for stage I-III disease? Int J Radiat Oncol Biol Phys 2013, 85:196-200.
• [21]Nakamura H, Kato Y, Kato H: Outcome of surgery for small-cell lung cancer—response to induction chemotherapy predicts survival. Thorac Cardiovasc Surg 2004, 52:206-210.
• [22]Ogawa S, Horio Y, Yatabe Y, Fukui T, Ito S, Hasegawa Y, Mitsudomi T, Hida T: Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. Int J Clin Oncol 2012, 17:218-224.
• [23]Bischof M, Debus J, Herfarth K, Muley T, Kappes J, Storz K, Hoffmann H: Surgery and chemotherapy for small-cell lung cancer in stages I–II with or without radiotherapy. Strahlenther Onkol 2007, 183:679-684.